ARCHIVES

NCI advisors approve recompetition of $62 million phase II contracts program.

This article is from The Cancer Letter archive.

Vol. 30 No. 44 | November 19, 2004

Download PDF Visit The Full Archive

Related Articles

ODAC Endorses Tamoxifen Trial, With Modification to Ensure Enrollment of Women At Higher Risk

August 2, 1991

Skipper’s Impact: Drugs Curing 40,000 a Year

March 27, 1981

Von Eschenbach Candidacy for FDA Hampered By Three Republican Holds.

December 1, 2006

NCI’s Oral Cancer Chemoprevention Trial On Hold After Fraud Allegations In Norway.

January 27, 2006

FDA Likely To Change Procedures For Patient Interaction, Official Says

November 10, 1995

NCI Research Grant Funding To Exceed $1.5 Billion, Support 4,800 Grants, In FY00.

January 14, 2000